| Objective:To assess the clinical effects and safety of Chinese herb inj ection(CHI)combined gemcitabine and cisplatin(GP)for non-small cell lung cancer(NSCLC).Through retrospective statistical analysis the use of Kanglaite injection of in-patients’ medical records,and to study Kanglaite injection information of clinical usage and combination,for clinical rational use of and provides some references for the further safty usage of clinical.Methods:1.The relative randomized controlled trials(RCTs)of CHIs were searched from CNKI、Pubmed、Cochrane Library、Web of Science、Wangfang Data and Traditional Chinese Medical Database system.The RCTs were screened according to the predefined inclusion and exclusion criteria,the related items were used to assess the quality of RCTs,data were analyzed by Wingbugs software.2.By using hospital information system to extract in-patients’ personal information and clinical drug Information of 2017-2020.and then the information standardization processing;finally application of Excel2010,SPSS19.0 and Clementine 12.0 software to the standardized data for statistical analysisResults:1.Network meta-analysisThe result of network meta-analysis showed that there were two significant difference between Aidi injection+GP or compound matrine inj ection+GP and GP regimen in effective rate;there were significant difference between Aidi injection and kanglaite injection and compound matrine injection Delisheng injection and Shenqifuzheng injection and Xiao’aiping injection and Shenmai injection and Brucea injection in quality of life.At the same time,there were no difference between 14 CHIs in leukopenia and nausea and vomiting.2.Patient information statisticsFor 1517 patients information statistics,833 Male cases(54.9%);684 female cases(45.1%);Patients with minimum age is 16,maximum age is 96,the average age is 68 years old;this part is the 54.2%of the whole what mainly concentrated in between the ages of 60 to 80;There are 322 cases of lung cancer(21.2%),followed by 238 cases of colorectal cancer(15.9%)and 166 cases of gastric cancer(10.9%)of all in-patients’information;Besides 862 no record case:Ⅰ period 19 cases(1.3%),Ⅱ period 39 cases(2.6%),Ⅲ period 73 cases(4.8%),Ⅳ 524 cases(34.5%);There is a family history of record(immediate family or collateral relatives within three generations and husband and wife),364 cases(24.0%),a record history of drug allergy patients in 306 cases(20.2%);There is a record of 24 patients with food allergy accounted for 1.6%.3.Kanglaite injection clinical information statisticsBy analysis of 1987 cases of independent medical records,we find that Kanglaite injection clinical use once a day,ivgtt.The often dosage of Kanglaite injection is 200 ml which accounted for 92.7%and the daily maximum usage of 200 ml,the minimum dosage is 100 ml.The top three treatment period is 21 days(9.6%),14 days(6.2%),and 8 days(5.5%),with an averageperiod of 13 days.The majority treatment period is 11-20 days(834 cases,42.0%),followed by 1-10 days(827 cases,41.6%).4.The drugs combination analysisStatistics the overall situation of combination and found that the top ten of clinical use are heparin sodium injection,potassium chloride injection,methoxylopramine hydrochloride injection,insulin injection,human albumin,furoxime injection,Xiaoaiping injection,ambuloxol hydrochloride injection,reduced glutathione for injection.In the analysis of combined drug use in patients with lung cancer,colorectal cancer and gastric cancer,anti-emetic drugs,immune function drugs and anti-tumor traditional Chinese medicine injections in the digestive system are mainly used,specifically methoxylopramine hydrochloride,recombinant human interleukin-2 for injection,xiaocancer-ping injection,etc.5.Weighted TOPSIS method for analysisAmong the 1987 cases,129(56.8%)had relative degree of proximity of no less than 80%,658(33.1%)between 60%to 80%,and 200(10.1%)less than 60%.Conclusion:1.Network meta-analysisBased on the result of network meta-analysis and rank,astragalus polysaccharide injection,compound matrine injection,Aidi injection were better than other Chinese herb injection(CHI).2.Evaluation of clinic Suitability Based on Kanglaite InjectionKanglaite injection usage、dosing frequency、applicable user are in accordance with instructions.Using TOPSIS to analysis Kanglaite injection.there are some differences between Kanglaite injection and the instruction in terms of dose and treatment period,which are mainly reflected in short of period and insufficient dose.3.The occurrence of adverse reactionsIn the clinical research of adverse reaction,437 cases of adverse reactions occurred in the 1987 independent medical records,mainly were gastrointestinal adverse reactions and fever.The incidence of adverse reactions was higher in women than in men;Due to the particularity of the patient who were older and in poor physical condition,besides most most of the adverse reactions were gastrointestinal symptoms,the occurrence of adverse reactions cannot be directly correlated with the use of Kanglaite injection according to the above information and still need further research.4.The drug combination of clinic researchThrough the analysis of the overall situation of the combined use of kanglaite injection,it can be seen that in the clinical treatment of kanglaite injection,it is mainly used in combination with nutritional supplements,digestive system drugs and anti-tumor traditional Chinese medicine injections.Second,analyzing the combination in patients with lung cancer,according to the results to palliative care of patients with combined frequency higher for expectorant anti-asthmatic and anti-nausea drug,take chemotherapy for patients with lung cancer mainly anti-nausea drug,immunity regulator,such as anti-tumor TCM injections used more,mostly preventive medication,in order to reduce the chemotherapy of the occurrence of adverse reactions such as nausea and vomiting,therefore,clinical combination is appropriate. |
PDF Full Text Request